ProCE Banner Activity

A 44-Year-Old Patient With Rapidly Progressing Metastatic TNBC Who Receives Sacituzumab Govitecan

Clinical Thought

Read this expert commentary discussing a 44-year-old woman with recurring advanced TNBC who received treatment with sacituzumab govitecan, an FDA-approved Trop-2–directed antibody and topoisomerase inhibitor conjugate, in the relapsed/refractory setting.

Released: November 14, 2022

Expiration: November 13, 2023

Share

Faculty

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Gilead Sciences, Inc.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Laura M. Spring, MD: consultant/advisor/speaker: Novartis, Puma; researcher: Genentech, Merck, Phillips.